Crestwood Advisors Group LLC Cuts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Crestwood Advisors Group LLC reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,926 shares of the medical equipment provider’s stock after selling 337 shares during the period. Crestwood Advisors Group LLC’s holdings in Hologic were worth $355,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in HOLX. FMR LLC grew its stake in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after buying an additional 544,889 shares during the last quarter. Swedbank AB raised its holdings in shares of Hologic by 18.8% during the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after buying an additional 306,562 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Hologic by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after buying an additional 238,222 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Hologic by 47.6% during the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock valued at $58,507,000 after acquiring an additional 231,578 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on HOLX. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Evercore ISI decreased their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. UBS Group lifted their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Morgan Stanley reduced their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research note on Monday, February 3rd. Ten equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Hologic currently has an average rating of “Moderate Buy” and a consensus price target of $85.77.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.88% of the stock is currently owned by insiders.

Hologic Stock Performance

NASDAQ:HOLX opened at $65.23 on Wednesday. The firm’s 50-day moving average is $69.62 and its 200-day moving average is $76.28. Hologic, Inc. has a 52-week low of $62.69 and a 52-week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company has a market cap of $14.64 billion, a price-to-earnings ratio of 20.58, a PEG ratio of 2.14 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.